Small Molecule Targeted Cancer Therapy Market Size, Share, Trends, Growth Report 2032

Small Molecule Targeted Cancer Therapy Market: Size

The Global small molecule targeted cancer therapy market size was worth around USD 83.41 billion in 2023 and is estimated to grow to about USD 188.78 billion by 2032, with a compound annual growth rate (CAGR) of approximately 9.50% over the forecast period.

Request Free Sample

The report covers forecast and analysis for the small molecule targeted cancer therapy market on a global and regional level. The study provides historic data from 2018 to 2022 along with a forecast from 2024 to 2032 based on revenue (USD Billion).

Small Molecule Targeted Cancer Therapy Market: Overview

Small molecule targeted cancer therapy is an advanced approach in oncology that involves the use of small, bioactive compounds designed to interfere with specific molecular targets involved in the growth, progression, and spread of cancer. Unlike traditional chemotherapy, which attacks rapidly dividing cells indiscriminately, targeted therapies aim to block the action of specific proteins, genes, or pathways that are crucial for cancer cell survival and proliferation.

Targeted cancer therapy uses drugs that specifically target cancer-specific proteins, genes, and tissue environment that assists in cancer cells’ growth and survival. These proteins or genes are found in cancerous cells or blood vessel cells that are related to cancer growth. Targeted therapy uses signal transduction inhibitors, hormone therapies, angiogenesis inhibitors, apoptosis inducers, gene expression modulators, immunotherapies, monoclonal antibodies, etc. Small molecule targeted therapy generally uses molecules of ≤5000 Da and is administered via the oral route. Due to their small size, these molecules can easily translocate through the plasma membrane and can interact with intracellular signaling molecules and cell-surface receptors’ cytoplasmic domain.

The study includes drivers and restraints for the small molecule targeted cancer therapy market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the small molecule targeted cancer therapy market on a global as well as regional level.

In order to give the users of this report a comprehensive view of the small molecule targeted cancer therapy market we have included a competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all segments are benchmarked based on their market size, growth rate, and general attractiveness.

Request Free Sample

The report provides a company market share analysis in order to give a broader overview of the key players in the small molecule targeted cancer therapy market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new type launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the small molecule targeted cancer therapy market on a global and regional basis.

Small Molecule Targeted Cancer Therapy Market: Growth Factors

The demand for small molecule targeted cancer therapy market is driven by the growing preference for cancer therapies with minimal adverse events, increasing cancer prevalence and increasing awareness. Additionally, the growing adoption of targeted therapy over chemotherapy, increasing health spending and disposable are important factors that boost the market growth. However, a slower drug approval process, stringent regulatory requirements, and high operational costs may limit the market growth over the forecast period. The patent expiry of major drugs is expected to bring growth opportunities over the forecast period for the global small molecule targeted cancer therapy market.

Small Molecule Targeted Cancer Therapy Market: Segmentation

The study provides a crucial view on the small molecule targeted cancer therapy by segmenting the market based on type, and region. All the segments of small molecule targeted cancer therapy market have been analyzed based on present and future trends and the market is estimated from 2024 to 2032.

Based on type, the global small molecule targeted cancer therapy market is segmented into small molecule drug conjugates, small molecules, and monoclonal antibodies. The small molecules type segment accounted for the largest market share in 2023 due to its effectiveness and lesser side effects. The small molecule type segment is sub-segmented into a small molecule tyrosine kinase inhibitor, a proteasome inhibitor, and a small molecule cyclin-dependent kinase inhibitor. The monoclonal antibodies segment is further split into humanized monoclonal antibodies, chimeric monoclonal antibodies, and fully human antibody. Thus upper eyelid surgeries are the most common and account for the largest market share. Small molecule drug conjugates segment is projected to witness the highest growth over the forecast period.

Small Molecule Targeted Cancer Therapy Market: Report Scope:

Small Molecule Targeted Cancer Therapy Market: Regional Insights

North America dominated the global small molecule targeted cancer therapy market in 2018. Increasing cancer prevalence, favorable reimbursement policies, presence of advanced health facilities, increasing health spending, and increasing preference for therapies with minimal side effects are factors driving the market in this region. Europe was the second largest regional small molecule targeted cancer therapy market.

Growing awareness about cancer and advanced therapies, and faster adoption of novel therapies are major factors that boost market growth in this region. Latin America is projected to exhibit moderate growth over the forecast period. Asia Pacific region will register the highest CAGR for the small molecule targeted cancer therapy market during the forecast period.

A large population base, increasing cancer prevalence, growth in demand for targeted therapy with lesser side effects than chemotherapy, government initiatives to create awareness, and increasing healthcare spending are factors promoting small molecule targeted cancer therapy market growth in Asia Pacific. The Middle East and Africa region is estimated to show slower growth in the coming years.

Small Molecule Targeted Cancer Therapy Market: Competitive Players

Major players included in the report are 

• Abbott Laboratories
• Bayer HealthCare AG
• Boehringer Ingelheim GmbH
• GlaxoSmithKline plc
• Hospira Inc.
• Cytokinetics Inc. 
• OncoGenex Pharmaceuticals. Inc. 
• Among others

The report segment of global small molecule targeted cancer therapy market as follows:

Global Small Molecule Targeted Cancer Therapy Market: By Type

• Monoclonal Antibodies
  • Fully Human Antibody
  • Chimeric Monoclonal Antibody
  • Humanized Monoclonal Antibody
• Small Molecules
  • Small Molecule Cyclin-dependent Kinase Inhibitor
  • Small Molecule Proteasome Inhibitor
  • Small Molecule Tyrosine Kinase Inhibitor
• Small Molecule Drug Conjugates

Global Small Molecule Targeted Cancer Therapy Market: By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa